2型糖尿病降糖药物治疗进展:更加关注心血管及肾脏结局  

Advances in the treatment of type 2 diabetes mellitus with glucose-lowering medications: more attention to cardiovascular and renal outcomes

作　　者：姚佳舒 孙子林[1] 袁扬[1] YAO Jiashu;SUN Zilin;YUAN Yang(Department of Endocrinology,Zhongda Hospital Affiliated to Southeast University,Nanjing 210009,China)

机构地区：[1]东南大学附属中大医院内分泌科,南京210009

出　　处：《中国糖尿病杂志》2021年第3期224-228,共5页Chinese Journal of Diabetes

基　　金：国家重点研发计划(2016YFC1305700)。

摘　　要：T2DM治疗的选择范围近年来有所扩展。动脉粥样硬化性心血管疾病是T2DM患者主要死因,应以预防或延缓其发生发展、提高患者生活质量为T2DM治疗目标。上世纪发明的Ins、二甲双胍和磺酰脲类药物是目前普遍使用的治疗药物,近年来新型降糖药,如钠-葡萄糖协同转运蛋白2抑制剂、胰升血糖素样肽1受体激动剂使患者心血管及肾脏获益增加。本文从关注T2DM患者心血管及肾脏结局角度,对T2DM降糖药物治疗进展进行综述。Treatment options for diabetes have expanded over recent years. Atherosclerotic cardiovascular disease is the leading cause of death in patients with type 2 diabetes mellitus(T2DM). The goals of treatment for T2DM are to prevent or delay complications and maintain quality of life. Insulin,metformin and sulfonylureas,which were discovered more than 50 years ago,remain established therapies. Some of the SGLT-2 inhibitors and GLP-1 receptor agonists have demonstrated not only non-inferiority but also superiority for cardiovascular and renal outcomes. This review provides the progress in the treatment of the glucose-lowering medications and focus the update on the latest evidence regarding the cardiovascular and renal effects of these newer classes of medications.

关 键 词：糖尿病 2型 降糖药物 心血管疾病 肾脏疾病 

分 类 号：R587.1[医药卫生—内分泌]